Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18212277 | 0.87 | HPGD (0.33) | MGLLHPGDNPSR1 | |
| SCHEMBL17262434 | 0.83 | MGMT (0.40) | MGMTMGLLABCG2GAA | |
| SCHEMBL18212279 | 0.82 | GAA (0.39) | GAA | |
| SCHEMBL25495612 | 0.82 | MGMT (0.42) | MGMTMGLLABCG2 | |
| SCHEMBL14499669 | 0.80 | HPGD (0.50) | HPGDNPSR1GAA | |
| SCHEMBL30455579 | 0.78 | MGMT (0.39) | MGMTMGLLABCG2 | |
| SCHEMBL30459733 | 0.78 | MGMT (0.39) | MGMTMGLLABCG2 | |
| SCHEMBL29199650 | 0.78 | HPGD (0.49) | MGMTHPGDNPSR1GAA | |
| SCHEMBL30458078 | 0.78 | MGMT (0.42) | MGMTMGLLABCG2 | |
| SCHEMBL26349179 | 0.78 | MGMT (0.42) | MGMTMGLLABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260291-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | SORRENTO THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20160326266-A1 | Chemically-Locked Bispecific Antibodies | SORRENTO THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260291-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | MGMT 2169/4885MGLL 1671/4885ABCG2 829/4885 |
| US-20160326266-A1 | Chemically-Locked Bispecific Antibodies | FCGR3B, FCGR2A, FCGR1A | MGMT 2169/4885MGLL 1671/4885ABCG2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.